Home  >  News
News
+ Font Resize -

Vivimed Labs gets additional US$ 7.5 mn funds from OrbiMed Asia for its overseas subsidiary

Our Bureau, Mumbai
Tuesday, January 2, 2018, 15:00 Hrs  [IST]

Vivimed Labs, a Hyderabad-based pharmaceuticals & speciality chemcials company, has signed definitive agreements and received funds to facilitate additional investment of US$ 7.5 million from OrbiMed Asia, a leading healthcare investment firm,  into the company's subsidiary, Vivimed Labs (Mascarene) Ltd, the holding entity of the company's API business. Earlier, OrbiMed invested $42.5 million in September 2017.

Santosh Varalwar, managing director, said, “Vivimed welcomes the additional follow on investment by OrbiMed Asia and this reiterates the confidence of the investor in the Vivimed Business model in he dynamic health care industry. The additional funds will fuel its growth opportunities overall.”

Saurabh Gurnurkar, executive director, Uquifa added, “The proceeds of this additional investment will be utilised todrive business growth and, increase the company's profitability by organic and inorganic growth opportunities.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |